CAMBRIDGE, Mass. — October 30, 2025 — Leads & Copy — Prime Medicine, Inc. (Nasdaq: PRME) will host a virtual event on November 12, 2025, to discuss its liver disease franchise and strategy, focusing on Wilson’s Disease.
The company is on track to file an investigational new drug (IND) or clinical trial application (CTA) for PM577, its Prime Editor for H1069Q-driven Wilson’s Disease, in the first half of 2026, with initial clinical data expected in 2027.
Presentations will feature Prime Medicine’s management team and Dr. Michael Schilsky from Yale School of Medicine, highlighting the company’s strategy to develop Prime Editors for genetic liver diseases, the Wilson’s Disease treatment landscape, and Prime Editing’s potential to cure Wilson’s Disease.
The event will be webcast live; pre-registration is available here. The live webcast and presentation materials will be on Prime Medicine’s Investor Relations webpage, with an archived replay available later.
Prime Medicine is focused on delivering a new class of differentiated one-time curative genetic therapies using its proprietary Prime Editing platform. They are progressing a diversified portfolio of investigational therapeutic programs focused on liver, lung, immunology and oncology.
Gregory Dearborn
Prime Medicine
857-209-0696
gdearborn@primemedicine.com
Hannah Deresiewicz
Precision AQ
212-362-1200
hannah.deresiewicz@precisionaq.com
Source: Prime Medicine
